FDA ALERT: FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

The US Food and Drug Administration (FDA) has approved Casgevy (exagamglogene autotemcel) for the treatment of patients aged 12 years and older with sickle cell disease (SCD) and recurrent vaso-occlusive crises. Casgevy is the first FDA-approved CRISPR/Cas9 genome-edited cell therapy, offering a one-time treatment approach for eligible patients with sickle cell disease.

Mechanism of Action  Casgevy is an autologous CD34+ hematopoietic stem cell therapy modified using CRISPR/Cas9 technology. It works by editing the BCL11A gene enhancer to increase fetal hemoglobin (HbF) production, which helps: Reduce red blood cell sickling Improve oxygen delivery Reduce vaso-occlusive complications  Clinical Evidence Supporting Approval  Key findings from clinical studies included: Reduction in severe vaso-occlusive crises Sustained increase in fetal hemoglobin levels Durable response following…